vs
Apellis Pharmaceuticals, Inc.（APLS）与SANFILIPPO JOHN B & SON INC（JBSS）财务数据对比。点击上方公司名可切换其他公司
SANFILIPPO JOHN B & SON INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.6倍（$314.8M vs $199.9M），SANFILIPPO JOHN B & SON INC净利率更高（5.7% vs -29.5%，领先35.2%），SANFILIPPO JOHN B & SON INC同比增速更快（4.6% vs -5.9%），SANFILIPPO JOHN B & SON INC自由现金流更多（$40.0M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 7.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
John B. Sanfilippo & Son Inc.（股票代码JBSS）是美国领先的坚果零食加工分销商，主营树坚果、花生、果干及增值零食产品，为北美零售、餐饮及工业原料客户提供自有品牌和贴牌产品。
APLS vs JBSS — 直观对比
营收规模更大
JBSS
是对方的1.6倍
$199.9M
营收增速更快
JBSS
高出10.5%
-5.9%
净利率更高
JBSS
高出35.2%
-29.5%
自由现金流更多
JBSS
多$54.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
7.6%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $314.8M |
| 净利润 | $-59.0M | $18.0M |
| 毛利率 | — | 18.8% |
| 营业利润率 | -25.6% | 8.3% |
| 净利率 | -29.5% | 5.7% |
| 营收同比 | -5.9% | 4.6% |
| 净利润同比 | -62.2% | 32.1% |
| 每股收益（稀释后） | $-0.40 | $1.53 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSJBSS
| Q4 25 | $199.9M | $314.8M | ||
| Q3 25 | $458.6M | $298.7M | ||
| Q2 25 | $178.5M | $269.1M | ||
| Q1 25 | $166.8M | $260.9M | ||
| Q4 24 | $212.5M | $301.1M | ||
| Q3 24 | $196.8M | $276.2M | ||
| Q2 24 | $199.7M | $269.6M | ||
| Q1 24 | $172.3M | $271.9M |
净利润APLSJBSS
| Q4 25 | $-59.0M | $18.0M | ||
| Q3 25 | $215.7M | $18.7M | ||
| Q2 25 | $-42.2M | $13.5M | ||
| Q1 25 | $-92.2M | $20.2M | ||
| Q4 24 | $-36.4M | $13.6M | ||
| Q3 24 | $-57.4M | $11.7M | ||
| Q2 24 | $-37.7M | $10.0M | ||
| Q1 24 | $-66.4M | $13.5M |
毛利率APLSJBSS
| Q4 25 | — | 18.8% | ||
| Q3 25 | — | 18.1% | ||
| Q2 25 | — | 18.1% | ||
| Q1 25 | — | 21.4% | ||
| Q4 24 | — | 17.4% | ||
| Q3 24 | — | 16.9% | ||
| Q2 24 | — | 18.5% | ||
| Q1 24 | — | 18.1% |
营业利润率APLSJBSS
| Q4 25 | -25.6% | 8.3% | ||
| Q3 25 | 48.7% | 9.0% | ||
| Q2 25 | -18.6% | 7.5% | ||
| Q1 25 | -50.0% | 10.8% | ||
| Q4 24 | -12.3% | 6.4% | ||
| Q3 24 | -24.0% | 6.2% | ||
| Q2 24 | -14.7% | 5.4% | ||
| Q1 24 | -36.0% | 6.7% |
净利率APLSJBSS
| Q4 25 | -29.5% | 5.7% | ||
| Q3 25 | 47.0% | 6.3% | ||
| Q2 25 | -23.6% | 5.0% | ||
| Q1 25 | -55.3% | 7.7% | ||
| Q4 24 | -17.1% | 4.5% | ||
| Q3 24 | -29.2% | 4.2% | ||
| Q2 24 | -18.9% | 3.7% | ||
| Q1 24 | -38.5% | 5.0% |
每股收益（稀释后）APLSJBSS
| Q4 25 | $-0.40 | $1.53 | ||
| Q3 25 | $1.67 | $1.59 | ||
| Q2 25 | $-0.33 | $1.15 | ||
| Q1 25 | $-0.74 | $1.72 | ||
| Q4 24 | $-0.30 | $1.16 | ||
| Q3 24 | $-0.46 | $1.00 | ||
| Q2 24 | $-0.30 | $0.85 | ||
| Q1 24 | $-0.54 | $1.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $2.4M |
| 总债务越低越好 | — | $28.8M |
| 股东权益账面价值 | $370.1M | $370.1M |
| 总资产 | $1.1B | $617.7M |
| 负债/权益比越低杠杆越低 | — | 0.08× |
8季度趋势，按日历期对齐
现金及短期投资APLSJBSS
| Q4 25 | $466.2M | $2.4M | ||
| Q3 25 | $479.2M | $714.0K | ||
| Q2 25 | $370.0M | $585.0K | ||
| Q1 25 | $358.4M | $1.3M | ||
| Q4 24 | $411.3M | $336.0K | ||
| Q3 24 | $396.9M | $442.0K | ||
| Q2 24 | $360.1M | $484.0K | ||
| Q1 24 | $325.9M | $377.0K |
总债务APLSJBSS
| Q4 25 | — | $28.8M | ||
| Q3 25 | — | $29.8M | ||
| Q2 25 | — | $14.6M | ||
| Q1 25 | — | $5.8M | ||
| Q4 24 | — | $6.0M | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | — | $6.4M | ||
| Q1 24 | $93.1M | $6.6M |
股东权益APLSJBSS
| Q4 25 | $370.1M | $370.1M | ||
| Q3 25 | $401.2M | $362.8M | ||
| Q2 25 | $156.3M | $360.7M | ||
| Q1 25 | $164.2M | $346.6M | ||
| Q4 24 | $228.5M | $325.6M | ||
| Q3 24 | $237.1M | $310.8M | ||
| Q2 24 | $264.3M | $322.6M | ||
| Q1 24 | $266.7M | $321.8M |
总资产APLSJBSS
| Q4 25 | $1.1B | $617.7M | ||
| Q3 25 | $1.1B | $598.7M | ||
| Q2 25 | $821.4M | $597.6M | ||
| Q1 25 | $807.3M | $590.0M | ||
| Q4 24 | $885.1M | $545.3M | ||
| Q3 24 | $901.9M | $519.4M | ||
| Q2 24 | $904.5M | $515.6M | ||
| Q1 24 | $831.9M | $491.9M |
负债/权益比APLSJBSS
| Q4 25 | — | 0.08× | ||
| Q3 25 | — | 0.08× | ||
| Q2 25 | — | 0.04× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | 0.35× | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $62.5M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $40.0M |
| 自由现金流率自由现金流/营收 | -7.1% | 12.7% |
| 资本支出强度资本支出/营收 | 0.1% | 7.1% |
| 现金转化率经营现金流/净利润 | — | 3.48× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $32.8M |
8季度趋势，按日历期对齐
经营现金流APLSJBSS
| Q4 25 | $-14.2M | $62.5M | ||
| Q3 25 | $108.5M | $32.1M | ||
| Q2 25 | $4.4M | $36.5M | ||
| Q1 25 | $-53.4M | $-25.9M | ||
| Q4 24 | $19.4M | $11.0M | ||
| Q3 24 | $34.1M | $8.9M | ||
| Q2 24 | $-8.3M | $35.2M | ||
| Q1 24 | $-133.0M | $5.3M |
自由现金流APLSJBSS
| Q4 25 | $-14.3M | $40.0M | ||
| Q3 25 | $108.3M | $7.3M | ||
| Q2 25 | $4.4M | $23.0M | ||
| Q1 25 | $-53.4M | $-37.6M | ||
| Q4 24 | $19.3M | $-2.7M | ||
| Q3 24 | — | $-3.0M | ||
| Q2 24 | $-8.4M | $24.4M | ||
| Q1 24 | $-133.3M | $-1.3M |
自由现金流率APLSJBSS
| Q4 25 | -7.1% | 12.7% | ||
| Q3 25 | 23.6% | 2.4% | ||
| Q2 25 | 2.5% | 8.6% | ||
| Q1 25 | -32.0% | -14.4% | ||
| Q4 24 | 9.1% | -0.9% | ||
| Q3 24 | — | -1.1% | ||
| Q2 24 | -4.2% | 9.0% | ||
| Q1 24 | -77.3% | -0.5% |
资本支出强度APLSJBSS
| Q4 25 | 0.1% | 7.1% | ||
| Q3 25 | 0.0% | 8.3% | ||
| Q2 25 | 0.0% | 5.0% | ||
| Q1 25 | 0.0% | 4.5% | ||
| Q4 24 | 0.0% | 4.5% | ||
| Q3 24 | 0.0% | 4.3% | ||
| Q2 24 | 0.0% | 4.0% | ||
| Q1 24 | 0.2% | 2.4% |
现金转化率APLSJBSS
| Q4 25 | — | 3.48× | ||
| Q3 25 | 0.50× | 1.72× | ||
| Q2 25 | — | 2.70× | ||
| Q1 25 | — | -1.29× | ||
| Q4 24 | — | 0.81× | ||
| Q3 24 | — | 0.77× | ||
| Q2 24 | — | 3.52× | ||
| Q1 24 | — | 0.39× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
JBSS
| Sales Channel Directly To Consumer | $263.2M | 84% |
| Sales Channel Commercial Ingredients | $28.0M | 9% |
| Sales Channel Contract Packaging | $23.6M | 8% |
